Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Blood Année : 2022

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study

(1, 2) , (3, 4) , (5) , (6) , (7) , (8) , (9) , (10) , (11) , (12, 13, 14, 15, 16) , (17, 18) , (19) , (20) , (21, 22) , (23, 24) , (25) , (26, 27) , (28) , (29) , (26, 30) , (31) , (32) , (33) , (34)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
Christophe Fruchart
  • Fonction : Auteur
Lysiane Molina
  • Fonction : Auteur
Guillaume Cartron
Franck Morschhauser
  • Fonction : Auteur correspondant
  • PersonId : 945614

Connectez-vous pour contacter l'auteur

Résumé

Obinutuzumab and lenalidomide (referred to as the GALEN combination) is an active immunomodulatory combination with a manageable safety profile in multiple types of lymphoma. We report efficacy and safety results for the phase 2 GALEN study in previously untreated patients with advanced follicular lymphoma (FL). Eligible patients aged ≥18 years had an Eastern Cooperative Oncology Group performance status ≤2 and high-tumor burden, grade 1 to 3a FL. Induction treatment was obinutuzumab (1000 mg IV, days 8, 15, and 22, cycle 1; day 1, cycles 2-6) plus lenalidomide (20 mg/d, days 1-21, cycle 1; days 2-22, cycles 2-6) for six 28-day cycles. Maintenance included obinutuzumab (1000 mg every 2 cycles) plus lenalidomide (10 mg, days 2-22) for ≤12 cycles (year 1) followed by obinutuzumab (1000 mg every 56 days) for 6 cycles (year 2). The primary end point was complete response rate (CRR) after induction per the 1999 International Working Group criteria. From October 2015 to February 2017, a total of 100 patients were enrolled. CRR after induction was 47%, and the overall response rate (ORR) was 92%. Post hoc analyses per the 2014 Lugano classification, including patients with missing bone marrow assessments, identified an additional 13 patients fulfilling CRR criteria, resulting in a complete metabolic response of 80% and an ORR of 94%. At a median follow-up of 3.7 years, 3-year progression-free survival and overall survival were 82% and 94%, respectively. The most common adverse event was neutropenia (48% any grade; 47% grade ≥3). Only 2% of patients presented with febrile neutropenia; others were mainly grade ≤2. No other specific grade ≥3 toxicity occurred at a frequency >3%. Overall, these results showed promising clinical efficacy for the chemotherapy-free GALEN backbone in previously untreated patients with high tumor burden FL. Except for neutropenia, the safety profile of the combination is remarkable. The study was registered at clinicaltrials.gov as #NCT01582776.
Fichier principal
Vignette du fichier
Bachy et al-2021-Obinutuzumab plus lenalidomide (GALEN) in advanced, previously untreated.pdf (1.02 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03679319 , version 1 (16-06-2022)

Identifiants

Citer

Emmanuel Bachy, Roch Houot, Pierre Feugier, Krimo Bouabdallah, Reda Bouabdallah, et al.. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study. Blood, 2022, 139 (15), pp.2338-2346. ⟨10.1182/blood.2021013526⟩. ⟨hal-03679319⟩
55 Consultations
11 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More